Lipid Research Group, Faculty of Medicine, School of Medical Sciences, University of New South Wales Sydney, Sydney, NSW, Australia.
Adv Exp Med Biol. 2022;1377:119-127. doi: 10.1007/978-981-19-1592-5_9.
Diabetes is a worldwide public health issue, with the number of cases expected to reach 642 million by 2040. Patients with diabetes are at a two- to four-fold increased risk of developing cardiovascular disease. This chapter focuses on the anti-diabetic and cardioprotective functions of plasma high-density lipoproteins (HDLs). HDLs and the main HDL apolipoprotein, apoA-I, improves pancreatic beta cell function. ApoA-I also improves insulin sensitivity. The development of novel, bifunctional HDL-based interventions are a promising therapeutic option for the treatment of cardiometabolic diseases.
糖尿病是一个全球性的公共卫生问题，预计到 2040 年，病例数将达到 6.42 亿。糖尿病患者患心血管疾病的风险增加 2 至 4 倍。本章重点介绍了血浆高密度脂蛋白（HDL）的抗糖尿病和心脏保护功能。HDL 和主要的 HDL 载脂蛋白 apoA-I 可改善胰岛β细胞功能。apoA-I 还可改善胰岛素敏感性。新型、双功能 HDL 为治疗心血管代谢疾病提供了有希望的治疗选择。
